RBCG-N-RSV not checked

Biothervax SpA

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Intradermal vaccination with rBCG-N-RSV that expresses the N protein of the respiratory syncytial virus (RSV)”In the company’s words, NCT07762014 on ClinicalTrials.gov
Tested for
Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention
Main trialPhase 2
“This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.”In the company’s words, NCT07762014 on ClinicalTrials.gov

Other drugs for Respiratory Syncytial Virus Infection Prevention

All 20 drugs for Respiratory Syncytial Virus Infection Prevention

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 7 Sep 2027 rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RBCG-N-RSV

Following is part of Solo: you see every change to RBCG-N-RSV the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in